Business
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
SINGAPORE, July 6, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company
About this update from Cytomed Therapeutics Limited
[{"type":"text","content":"SINGAPORE, July 6, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (\"CytoMed\" or \"Company\"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor cell-based immunotherapies for the treatment of various cancers, announce that the CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has exclusively licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO).\n\n \n \n \n \n \n \n\n \nOur CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.The patent titled \"Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same\" covers technologies for the clinical-scale expansion of γδ T cells from a small amount of donor peripheral blood cells as well as the modification of the expanded γδ T cells to incorporate a chimeric antigen receptor (CAR) that enables the modified cells to recognize a wide range of cancers, including both solid and hematologic cancers. CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.\n\"We are pleased to announce our allogeneic CAR-γδ T cell technology has received a US patent especially when we are soon to embark on our first-in-human trial for CAR-γδ T cells in Singapore,\" said Peter Choo, Chairman of CytoMed. \"We expect to receive additional patent rights from other territories.\"\nCytoMed's CAR-γδ T cell technology is currently being developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens. The risk of \"on-target-off-cancer\" side effects may be reduced by targeting stress-induced antigens that are mainly expressed on cancer cells such as NKG2D ligands. The Company received approval in January 2023 from the Health Sciences Authority (HSA) in Singapore to conduct a Phase I clinical trial. The Phase I clinical trial will be conducted at the National University Hospital (NUH), Singapore, and is expected to initiate in the second half of 2023.\n\"We are glad that CytoMed Therapeutics is making progress in its efforts to deliver immunotherapies to treat cancers. A*STAR works closely with the industry to translate our research into clinical applications. Cancer is a...